Marked variability of monacolin levels in commercial red yeast rice products: Buyer beware!

Archives of Internal Medicine

Volumn 170, Issue 19, 2010, Pages 1722-1727

  Gordon, Ram Y ^a,b   Cooperman, Tod ^c   Obermeyer, William ^c   Becker, David J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ABINGTON MEMORIAL HOSPITAL   (United States)

^c ConsumerLabcom ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTIN; CHOLESTRIX; CITRININ; HEART AND CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MONACOLIN; MONACOLIN KA; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

ALTERNATIVE MEDICINE; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICAL COMPOSITION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIET SUPPLEMENTATION; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG LABELING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; MASS SPECTROMETRY; MYALGIA; NEPHROTOXICITY; PRIORITY JOURNAL; RICE; ANALYSIS; CHEMISTRY; COMPARATIVE STUDY; FOOD CONTROL; FOOD INDUSTRY; PROCEDURES; PRODUCT SAFETY; RETROSPECTIVE STUDY; STANDARDS; SUPPLY AND DISTRIBUTION;

BIOLOGICAL PRODUCTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; FOOD INDUSTRY; FOOD INSPECTION; HUMANS; LOVASTATIN; MASS SPECTROMETRY; RETROSPECTIVE STUDIES;

EID: 78049264831     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.382     Document Type: Article

References (40)

1. Knox J, Gaster B. Dietary supplements for the prevention and treatment of coronary artery disease. J Altern Complement Med. 2007;13(1):83-95.
2. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290(6):765-772.
3. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295(19):2262-2269.
4. Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy. 2001;21(4):481-487.
5. Praça JM, Thomaz A, Caramelli B. Eggplant (Solanum melongena) extract does not alter serum lipid levels. Arq Bras Cardiol. 2004;82(3):269-276.
6. Ulbricht C, Basch E, Szapary P, et al; Natural Standard Research Collaboration. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005;13(4):279-290.
7. Endo A, Monacolin K. A new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo). 1979;32(8):852-854.
8. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007;14(3):438-440.
9. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153(5):679-686.
10. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69(2):231-236.
11. Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal. 2004;35(5):1101-1112.
12. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830-839, W147-W149.
13. Becker DJ, Gordon RY, Morris PB, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83(7):758-764.
14. Mast C. Red yeast rice research triggers (mostly) positive news for supplements. http://blog.nutritionbusinessjournal.com/nbj/2009/06/16/red-yeast- rice-research-triggers-mostly-positive-news-for-supplements/. Accessed July 3, 2009.
15. Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm. 2000;57(10):963-969.
16. ConsumerLab.com. Product review of red yeast rice supplements. http://www.consumerlab.com/reviews/Red-Yeast-Rice-Supplements-Lovastatin- Monacolin/Red-Yeast-Rice/. Accessed July 3, 2009.
17. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328(4):246-252.
18. Cohen PA. American roulette - contaminated dietary supplements. N Engl J Med. 2009;361(16):1523-1525.
19. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
20. Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med. 1998;129(12):1061-1065.
21. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-1575.
22. Mast C. 2008 Nutrition industry overview. Nutrition Business J. 2008;13(6/7):3.
23. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7(2):133-139.
24. Kimpel P. The Cholestin case: drugs vs. supplements. http://iml.jou.ufl. edu/projects/Spring2000/Kimpel/cholestin.html. Accessed September 29, 2009.
25. Lu Z, Kou W, Du B, et al; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689-1693.
26. Li JJ, Lu ZL, Kou WR, et al; Chinese Coronary Secondary Prevention Study Group. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol. 2009;49(8):947-956.
27. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105(2):198-204.
28. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105(5):664-666.
29. Department of Health and Human Services; US Food and Drug Administration. Current good manufacturing practice in manufacturing, production, labeling, or holding operations for dietary supplements. http://www.fda.gov/ohrms/dockets/ 98fr/cf0441.pdf. Accessed August 27, 2010.
30. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.
31. Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66(4):572-574.
32. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145(6):474-475. (Pubitemid 46768586)
33. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J. 2003;96(12):1265-1267.
34. Vercelli L, Mongini T, Olivero N, Rodolico C, Musumeci O, Palmucci L. Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment. J Am Geriatr Soc. 2006;54(4):718-720.
35. Cartin-Ceba R, Lu LB, Kolpakchi A. A "natural" threat. Am J Med. 2007;120(11):e3-e4.
36. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med. 2008;149(7):516-517.
37. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74(8):1200-1201.
38. Sabater-Vilar M, Maas RF, Fink-Gremmels J. Mutagenicity of commercial Monascus fermentation products and the role of citrinin contamination. Mutat Res. 1999;444(1):7-16.
39. Endo A, Kuroda M. Citrinin, an inhibitor of cholesterol synthesis. J Antibiot (Tokyo). 1976;29(8):841-843.
40. Dönmez-Altuntas H, Dumlupinar G, Imamoglu N, Hamurcu Z, Liman BC. Effects of the mycotoxin citrinin on micronucleus formation in a cytokinesis-block genotoxicity assay in cultured human lymphocytes. J Appl Toxicol. 2007;27(4):337-341.